Vector Medical Technologies, Inc. Announces Met-enkephalin, Therapeutic Aids Vaccine

Apr 05, 2001, 01:00 ET from Vector Medical Technologies

    BOCA RATON, Fla., April 5 /PRNewswire/ -- Vector Medical Technologies,
 Inc. ("Vector" or "The Company"), announced that on April 4, 2001, at a
 meeting of the American Association of Immunologists held in the Orlando
 Convention Center, Nicholas P. Plotnikoff, Ph.D., Professor of Pharmacology at
 the University of Illinois Medical Center in Chicago and, a senior member of
 the 1977 Nobel Prize-winning team in medicine, presented his findings
 regarding Methinone Enkephalin ("Met-enkephalin"), in his presentation of
 Met-enkephalin, Therapeutic AIDS Vaccine.
     Professor Plotnikoff is Vice President of Research and Development of
 Vector Medical Technologies, Inc.  Professor Plotnikoff and his research team
 are conducting Phase II clinical trials in human beings that have shown that
 Met-enkephalin strengthens and dramatically increases the number of "killer"
 T-cells that destroy invading viruses, specifically the AIDS virus.  Professor
 Plotnikoff and his research team have demonstrated that it is possible to
 treat HIV-infected patients with Met-enkephalin and thereby increase the
 number of T-cells/killer cells that destroy the AIDS virus with no detrimental
 side effects such as those currently found in other present day treatments.
     Dr. Plotnikoff's studies to date have indicated that high T-cell/killer
 cell counts have been noticed in patients as well as a reduction of the AIDS
 virus within the blood stream, following infusions of Met-enkephalin.
 Professor Plotnikoff has indicated that this could result in the treatment of
 Met-enkephalin as a therapeutic AIDS vaccine.  Commenting on the studies,
 Professor Plotnikoff stated, "In the studies conducted to date, there have
 been noted increases in CD8 cells, or Cytotoxic T-cells, that attack the HIV
 virus.  Our clinical studies have demonstrated a reduction in the viral load
 and a reduction in the infections.  These studies have also demonstrated
 increased T-cell counts 30 and 60 days after treatment was discontinued."  The
 use of Met-enkephalin will be subject to further clinical testing and approval
 by the Federal Drug Administration ("FDA") before it may become available to
 the using public.
     Vector Medical Technologies, Inc. is a development stage biopharmaceutical
 technology company developing Met-enkephalin for the treatment of AIDS, as
 well as the research and development of a non-invasive transdermal delivery
 system for a wide variety of high-density molecular weight drugs such as
 Insulin, Collagen, Elastin and other large molecular weight compounds.  Such
 technology, if developed, approved by the appropriate governmental agencies
 and then commercialized, could enable the non-invasive delivery of drugs
 currently administered by injection.  Vector, through its collaboration and
 business relationships with various physicians, researchers, medical
 institutions and others, plans to develop, commercialize and market a variety
 of products for the transdermal delivery of macromolecule drugs, including
 Met-enkephalin.
     For further information regarding Met-enkephalin, please contact Michael
 H. Salit, M.D. at Vector Medical Technologies, Inc. 561-338-6330.
 
     Forward-Looking Statements: Certain statements contained in this release,
 including statements regarding the anticipated development and expansion of
 the Company's business, the intent, belief or current expectations of the
 Company, its directors or officers, primarily with respect to the future
 operating performance of the Company and other statements contained herein
 regarding matters that are not historical facts are "forward-looking"
 statements.  Because such statements include risks and uncertainties, actual
 results may differ materially from those expressed or implied by such forward-
 looking statements.  These risks and uncertainties include, but are not
 limited to, the potential inability of the Company to obtain adequate
 financing, the potential termination of contractual relationships, and the
 potential inability of the Company to obtain and maintain regulatory approval
 for its products, the potential inability to achieve satisfactory clinical
 trial results, market acceptance of and continuing demand for its products and
 the impact of competitive products and pricing.
 
 

SOURCE Vector Medical Technologies
    BOCA RATON, Fla., April 5 /PRNewswire/ -- Vector Medical Technologies,
 Inc. ("Vector" or "The Company"), announced that on April 4, 2001, at a
 meeting of the American Association of Immunologists held in the Orlando
 Convention Center, Nicholas P. Plotnikoff, Ph.D., Professor of Pharmacology at
 the University of Illinois Medical Center in Chicago and, a senior member of
 the 1977 Nobel Prize-winning team in medicine, presented his findings
 regarding Methinone Enkephalin ("Met-enkephalin"), in his presentation of
 Met-enkephalin, Therapeutic AIDS Vaccine.
     Professor Plotnikoff is Vice President of Research and Development of
 Vector Medical Technologies, Inc.  Professor Plotnikoff and his research team
 are conducting Phase II clinical trials in human beings that have shown that
 Met-enkephalin strengthens and dramatically increases the number of "killer"
 T-cells that destroy invading viruses, specifically the AIDS virus.  Professor
 Plotnikoff and his research team have demonstrated that it is possible to
 treat HIV-infected patients with Met-enkephalin and thereby increase the
 number of T-cells/killer cells that destroy the AIDS virus with no detrimental
 side effects such as those currently found in other present day treatments.
     Dr. Plotnikoff's studies to date have indicated that high T-cell/killer
 cell counts have been noticed in patients as well as a reduction of the AIDS
 virus within the blood stream, following infusions of Met-enkephalin.
 Professor Plotnikoff has indicated that this could result in the treatment of
 Met-enkephalin as a therapeutic AIDS vaccine.  Commenting on the studies,
 Professor Plotnikoff stated, "In the studies conducted to date, there have
 been noted increases in CD8 cells, or Cytotoxic T-cells, that attack the HIV
 virus.  Our clinical studies have demonstrated a reduction in the viral load
 and a reduction in the infections.  These studies have also demonstrated
 increased T-cell counts 30 and 60 days after treatment was discontinued."  The
 use of Met-enkephalin will be subject to further clinical testing and approval
 by the Federal Drug Administration ("FDA") before it may become available to
 the using public.
     Vector Medical Technologies, Inc. is a development stage biopharmaceutical
 technology company developing Met-enkephalin for the treatment of AIDS, as
 well as the research and development of a non-invasive transdermal delivery
 system for a wide variety of high-density molecular weight drugs such as
 Insulin, Collagen, Elastin and other large molecular weight compounds.  Such
 technology, if developed, approved by the appropriate governmental agencies
 and then commercialized, could enable the non-invasive delivery of drugs
 currently administered by injection.  Vector, through its collaboration and
 business relationships with various physicians, researchers, medical
 institutions and others, plans to develop, commercialize and market a variety
 of products for the transdermal delivery of macromolecule drugs, including
 Met-enkephalin.
     For further information regarding Met-enkephalin, please contact Michael
 H. Salit, M.D. at Vector Medical Technologies, Inc. 561-338-6330.
 
     Forward-Looking Statements: Certain statements contained in this release,
 including statements regarding the anticipated development and expansion of
 the Company's business, the intent, belief or current expectations of the
 Company, its directors or officers, primarily with respect to the future
 operating performance of the Company and other statements contained herein
 regarding matters that are not historical facts are "forward-looking"
 statements.  Because such statements include risks and uncertainties, actual
 results may differ materially from those expressed or implied by such forward-
 looking statements.  These risks and uncertainties include, but are not
 limited to, the potential inability of the Company to obtain adequate
 financing, the potential termination of contractual relationships, and the
 potential inability of the Company to obtain and maintain regulatory approval
 for its products, the potential inability to achieve satisfactory clinical
 trial results, market acceptance of and continuing demand for its products and
 the impact of competitive products and pricing.
 
 SOURCE  Vector Medical Technologies